Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2016

Open Access 01-12-2016 | Research

Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases

Authors: Nicolaus Andratschke, Alan Parys, Susanne Stadtfeld, Stefan Wurster, Stefan Huttenlocher, Detlef Imhoff, Müjdat Yildirim, Dirk Rades, Claus Michael Rödel, Jürgen Dunst, Guido Hildebrandt, Oliver Blanck

Published in: Radiation Oncology | Issue 1/2016

Login to get access

Abstract

Background

We retrospectively evaluated the efficacy and toxicity of gross tumor volume (GTV) mean-dose-optimized and real-time motion-compensated robotic stereotactic body radiation therapy (SBRT) in the treatment of liver metastases.

Methods

Between March 2011 and July 2015, 52 patients were treated with SBRT for a total of 91 liver metastases (one to four metastases per patient) with a median GTV volume of 12 cc (min 1 cc, max 372 cc). The optimization of mean GTV dose was prioritized during treatment planning at the potential cost of planning target volume (PTV) coverage reduction while adhering to safe normal tissue constraints. The delivered median GTV biological effective dose (BED10) was 142.1 Gy10 (range, 60.2 Gy10 –165.3 Gy10) and the prescribed PTV BED10 ranged from 40.6 Gy10 to 112.5 Gy10 (median, 86.1 Gy10). We analyzed local control (LC), progression-free interval (PFI), overall survival (OS), and toxicity.

Results

Median follow-up was 17 months (range, 2–49 months). The 2-year actuarial LC, PFI, and OS rates were 82.1, 17.7, and 45.0 %, and the median PFI and OS were 9 and 23 months, respectively. In univariate analysis histology (p < 0.001), PTV prescription BED10 (HR 0.95, CI 0.91–0.98, p = 0.002) and GTV mean BED10 (HR 0.975, CI 0.954–0.996, p = 0.011) were predictive for LC. Multivariate analysis showed that only extrahepatic disease status at time of treatment was a significant factor (p = 0.033 and p = 0.009, respectively) for PFI and OS. Acute nausea or fatigue grade 1 was observed in 24.1 % of the patients and only 1 patient (1.9 %) had a side effect of grade ≥ 2.

Conclusions

Robotic real-time motion-compensated SBRT is a safe and effective treatment for one to four liver metastases. Reducing the PTV prescription dose and keeping a high mean GTV dose allowed the reduction of toxicity while maintaining a high local control probability for the treated lesions.
Literature
1.
Bengtsson G, Carlsson G, Hafstrom L, et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg. 1981;141(5):586–9.CrossRefPubMed
2.
LeGolvan MP, Resnick M. Pathobiology of colorectal cancer hepatic metastases with an emphasis on prognostic factors. J Surg Oncol. 2010;102(8):898–908.CrossRefPubMed
3.
Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer. 2009;115(4):752–9.CrossRefPubMedPubMedCentral
4.
Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int. 2010;107(19):335–42.PubMedPubMedCentral
5.
Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13(1):51–64.CrossRefPubMed
6.
Baden H, Andersen B. Survival of patients with untreated liver metastases from colorectal cancer. Scand J Gastroenterol. 1975;10(2):221–3.PubMed
7.
Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994;116(4):703–10. discussion 10-1.PubMedPubMedCentral
8.
Thelen A, Jonas S, Benckert C, et al. Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol. 2007;33(3):324–8.CrossRefPubMed
9.
Martel G, Hawel J, Rekman J, et al. Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study. PLoS One. 2015;10(3):e0120569.CrossRefPubMedPubMedCentral
10.
Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007;109(4):718–26.CrossRefPubMed
11.
12.
Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17(4):1025–34.CrossRefPubMed
13.
Vogl TJ, Straub R, Eichler K, et al. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy--local tumor control rate and survival data. Radiology. 2004;230(2):450–8.CrossRefPubMed
14.
Moir JA, Burns J, Barnes J, et al. Selective internal radiation therapy for liver malignancies. Br J Surg. 2015;102(12):1533–40.CrossRefPubMed
15.
Sterzing F, Brunner TB, Ernst I, et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol. 2014;190(10):872–81.CrossRefPubMed
16.
van der Pool AE, Mendez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg. 2010;97(3):377–82.CrossRefPubMed
17.
Andratschke NH, Nieder C, Heppt F, et al. Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. Radiat Oncol. 2015;10:69.CrossRefPubMedPubMedCentral
18.
Habermehl D, Herfarth KK, Bermejo JL, et al. Single-dose radiosurgical treatment for hepatic metastases--therapeutic outcome of 138 treated lesions from a single institution. Radiat Oncol. 2013;8:175.CrossRefPubMedPubMedCentral
19.
Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543–53.CrossRefPubMed
20.
Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30.CrossRefPubMed
21.
Boda-Heggemann J, Dinter D, Weiss C, et al. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases - clinical results. Radiat Oncol. 2012;7:92.CrossRefPubMedPubMedCentral
22.
Kilby W, Dooley JR, Kuduvalli G, et al. The cyberknife robotic radiosurgery system in 2010. Technol Cancer Res Treat. 2010;9(5):433–52.CrossRefPubMed
23.
Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys. 2004;31(10):2738–41.CrossRefPubMed
24.
Vautravers-Dewas C, Dewas S, Bonodeau F, et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys. 2011;81(3):e39–47.CrossRefPubMed
25.
Méndez Romero A, Verheij J, Dwarkasing RS, et al. Comparison of macroscopic pathology measurements with magnetic resonance imaging and assessment of microscopic pathology extension for colorectal liver metastases. Int J Radiat Oncol Biol Phys. 2012;82(1):159–66.CrossRefPubMed
26.
Pepin EW, Wu H, Zhang Y, et al. Correlation and prediction uncertainties in the cyberknife synchrony respiratory tracking system. Med Phys. 2011;38(7):4036–44.CrossRefPubMedPubMedCentral
27.
Winter JD, Wong R, Swaminath A, Chow T. Accuracy of robotic radiosurgical liver treatment throughout the respiratory cycle. Int J Radiat Oncol Biol Phys. 2015;93(4):916–24.CrossRefPubMed
28.
Schlaefer A, Schweikard A. Stepwise multi-criteria optimization for robotic radiosurgery. Med Phys. 2008;35(5):2094–103.CrossRefPubMed
29.
Blanck O, Wang L, Baus W, et al. Inverse Treatment Planning for Spinal Robotic Radiosurgery: An International Multi-Institutional Benchmark Trial. J Appl Clin Med Phys. In Press.
30.
Grimm J, LaCouture T, Croce R, et al. Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys. 2011;12(2):3368. Review.PubMed
31.
Ernst F, Dürichen R, Schlaefer A, Schweikard A. Evaluating and comparing algorithms for respiratory motion prediction. Phys Med Biol. 2013;58(11):3911–29.CrossRefPubMed
32.
Kress MS, Collins BT, Collins SP, Dritschilo A, Gagnon G, Unger K. Stereotactic body radiation therapy for liver metastases from colorectal cancer: analysis of safety, feasibility, and early outcomes. Front Oncol. 2012;2:8.CrossRefPubMedPubMedCentral
33.
Lanciano R, Lamond J, Yang J, et al. Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors. Front Oncol. 2012;2:23.CrossRefPubMedPubMedCentral
34.
Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol. 2012;7:166.CrossRefPubMedPubMedCentral
35.
Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117(17):4060–9.CrossRefPubMed
36.
Stintzing S, Hoffmann RT, Heinemann V, et al. Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol. 2010;17(11):2877–83.CrossRefPubMed
37.
Esposito M, Maggi G, Marino C, et al. Multicentre treatment planning inter-comparison in a national context: The liver stereotactic ablative radiotherapy case. Phys Med. 2016;32(1):277–83.CrossRefPubMed
38.
Guckenberger M, Klement RJ, Allgäuer M, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. Radiother Oncol. 2016;118(3):485–91.CrossRefPubMed
39.
Ahmed KA, Fulp WJ, Berglund AE, et al. Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int J Radiat Oncol Biol Phys. 2015;92(4):837–42.CrossRefPubMed
40.
Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585–91.CrossRefPubMed
41.
Fonseca AZ, Santin S, Gomes LG, et al. Complications of radiofrequency ablation of hepatic tumors: Frequency and risk factors. World J Hepatol. 2014;6(3):107–13.CrossRefPubMedPubMedCentral
42.
43.
Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8.CrossRefPubMed
44.
Rule W, Timmerman R, Tong L, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–7.CrossRefPubMed
Metadata
Title
Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases
Authors
Nicolaus Andratschke
Alan Parys
Susanne Stadtfeld
Stefan Wurster
Stefan Huttenlocher
Detlef Imhoff
Müjdat Yildirim
Dirk Rades
Claus Michael Rödel
Jürgen Dunst
Guido Hildebrandt
Oliver Blanck
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2016
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-016-0652-4

Other articles of this Issue 1/2016

Radiation Oncology 1/2016 Go to the issue

Research

The efficacy of postoperative radiotherapy in localized primary soft tissue sarcoma treated with conservative surgery

Research

Resistance training concomitant to radiotherapy of spinal bone metastases – survival and prognostic factors of a randomized trial

Research

Target dose conversion modeling from pencil beam (PB) to Monte Carlo (MC) for lung SBRT

Research

Dosimetric impact of different bladder and rectum filling during prostate cancer radiotherapy

Research

Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)

Research

Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection